• Sumitomo Pharma and Novo Nordisk Pharma Enter into a Co-Promotion Agreement for Ozempic Subcutaneous Injection, a Treatment for Type 2 Diabetes, in Japan
  • Posted Notice of Convocation of the 205th Annual Shareholders' Meeting
  • (Progress of disclosure matters) Notice Regarding a Company Split (Simplified Absorption-Type Company Split) of the Asian Business and the Execution of a Share Transfer Agreement and a Shareholders' Agreement with Marubeni Global Pharma Corporation
  • Caution Regarding Suspicious Emails Impersonating the Company
  • Posted conference on FY2024​ Financial Results and​ Reboot 2027 – Reboot for a Strong Sumitomo Pharma – [Webcast]
  • Presentation Material (Conference on FY2024​ Financial Results and​ Reboot 2027 – Reboot for a Strong Sumitomo Pharma –)
  • Supplementary Financial Data (IFRS) for the Year Ended March 31, 2025
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2025 [IFRS]
  • Sumitomo Pharma Announces Reboot 2027 – Reboot for a Strong Sumitomo Pharma –
  • Notice Regarding the Estimated Recording of Gain on Transfer of Shares in Affiliated Companies
  • Notice Regarding Appointment of Executive and Other Key Personnel
  • Notice of Partial Amendment to the Articles of Incorporation
  • Announcement of Reduction in Executive Remuneration
  • Sumitomo Pharma Announces Organizational Realignment and Personnel Changes
  • Sumitomo Pharma Announces Revisions to Its Financial Forecasts and Recording of Gains from Transfer of Equity Interests
  • Notice Concerning Reversal of Allowance for Doubtful Accounts of Subsidiaries and Affiliates in Company’s Non-consolidated Financial Statements (Japanese GAAP)
  • Sumitomo Pharma Announces Changes in the Positions Assumed by Executive Officers and Other Key Position
  • Sumitomo Pharma Announces Reduction in Executive Remuneration
  • Notice Regarding a Company Split (Simplified Absorption-Type Company Split) of the Asian Business and the Execution of a Share Transfer Agreement and a Shareholders’ Agreement with Marubeni Global Pharma Corporation
  • Notice of Transition to Company with an Audit & Supervisory Committee
  • Notice Regarding the Transfer of Shares of Subsidiary
  • Notice Regarding Refinancing of Existing Borrowings Through a Syndicated Loan
  • Sumitomo Pharma Announces Changes in Executive Officers and Other Key Positions
  • Sumitomo Chemical Announces the New Corporate Business Plan FY2025 - FY2027
  • Notice of Capital Reorganization within Sumitomo Pharma Group
  • Sumitomo Pharma Selected as Highest Rating A-List Company by CDP in the Category of Climate Change in CDP 2024
  • Posted Conference on Q3 FY2024 Financial Results [Webcast]
  • Presentation Material (Conference on Q3 FY2024 Financial Results)
  • Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2025
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2025 [IFRS]
  • Sumitomo Pharma Announces Revisions to Its Financial Forecasts
  • Notice Concerning Finance Income
  • Sumitomo Pharma Announces Agreement on Co-Promotion Collaboration Partner for Marketing of PPLAT XEPLION and XEPLION TRI in Japan
  • Sumitomo Pharma Announces Organizational Realignment and Personnel Changes
  • Conference on the Establishment of RACTHERA, the Regenerative Medicine and Cell Therapy Business Joint Venture [Webcast]
  • Sumitomo Pharma America Announces U.S. FDA Approval of GEMTESA (vibegron) for Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
  • Sumitomo Pharma Announces Personnel Change
  • Sumitomo Pharma Presentation for the Conference on the Establishment of RACTHERA, the Regenerative Medicine and Cell Therapy Business Joint Venture
  • Sumitomo Chemical Presentation for the Conference on the Establishment of RACTHERA, the Regenerative Medicine and Cell Therapy Business Joint Venture
  • Sumitomo Chemical and Sumitomo Pharma to Establish Regenerative Medicine and Cell Therapy Joint Venture
  • Notice Regarding Company Split (Simplified Absorption-type Company Split) of the Regenerative Medicine and Cell Therapy Business and Transfer of Subsidiary Shares
  • Sumitomo Pharma America Presents New Data on Nuvisertib and Enzomenib at the 2024 American Society of Hematology Annual Meeting
  • Initiation of Phase1/2 Study on Allogeneic iPS Cell-derived Retinal Sheet for Retinitis Pigmentosa in the United States
  • Posted Conference on Q2 FY2024 Financial Results [Webcast]
  • Sumitomo Pharma America to Present New Investigational Data at the 2024 American Society of Hematology Annual Meeting
  • Sumitomo Pharma’s Subsidiary Concluded Agreement with Tokyo Metropolitan Government and the Tokyo Metropolitan Institute for Geriatrics and Gerontology Concerning a Health Promotion Project for the Elderly
  • Presentation Material (Conference on Q2 FY2024 Financial Results)
  • Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2025
  • Summary of Consolidated Financial Results for the Second Quarter (First Half) of the Year Ending March 31, 2025 [IFRS]
  • Sumitomo Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
  • Sumitomo Pharma Announces the Results of Its Early Retirement Program Offer to Employees in Japan for Business Structural Reform
  • Notice Concerning Finance Costs
  • Change in Ownership Ratio in Regenerative Medicine and Cell Therapy CDMO
  • Sumitomo Pharma Announces Change in Executive Officer
  • Sumitomo Pharma Announces Personnel Change
  • Sumitomo Pharma Selected for Five Inclusions as a Constituent of GPIF-Adopted ESG Indexes
  • Posted Conference on Q1 FY2024 Financial Results [Webcast]
  • Sumitomo Pharma Announces Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan
  • 【Joint press release】Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan
  • First Transplantation in Phase 1/2 Study of Allogeneic iPS Cell-Derived Retinal Pigment Epithelial Cells
  • Presentation Material (Conference on Q1 FY2024 Financial Results)
  • Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2025
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2025 [IFRS]
  • Sumitomo Pharma Announces Offering an Early Retirement Program to Employees in Japan for Business Structural Reform
  • Notice Concerning Finance Income
  • Sumitomo Pharma Announces that DSP-5336 Has Received FDA Fast Track Designation for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
  • Consolidated Financial Statements for Years ended March 31, 2024 and 2023
  • Sumitomo Pharma Presents New Clinical Data on DSP-5336 at the European Hematology Association 2024 Congress
  • Sumitomo Pharma Announces Organizational Realignment and Changes in the Positions Assumed by Executive Officer and Other Key Positions
  • Posted Notice of Convocation of the 204th Annual Shareholders' Meeting
  • Posted Conference on FY2023 Financial Results [Webcast]
  • Sumitomo Pharma Appoints Toru Kimura as President and CEO and Changes in Board of Directors Including Representative Directors, Executive Officer, and the Positions Assumed by Executive Officers
  • Presentation Material (Conference on FY2023 Financial Results)
  • Supplementary Financial Data (IFRS) for the Year Ended March 31, 2024
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2024 [IFRS]
  • Sumitomo Pharma Announces Reduction in Executive Remuneration
  • Start of Phase 1 Clinical Study on Novel Universal Influenza Vaccine Candidate
  • Sumitomo Pharma Announces FDA Acceptance of Supplemental New Drug Application for Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
  • Notice of Company Split (Simplified Absorption-type Company Split) of the Frontier Business and Notice of Business Acquisition by a Wholly-Owned Subsidiary of the Company
  • Posted Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024 [Webcast]
  • Presentation Material (Conference on Financial Forecasts Revision for FY2023 and Financial Forecasts for FY2024) (May 1, 2024)
  • Sumitomo Pharma Announces Its Financial Forecasts Revision for FY2023, Financial and Dividend Forecasts for FY2024
  • Notice Concerning Impairment Losses, Business Structure Improvement Expenses, and Finance Income
  • Notice Concerning Valuation Loss on Shares of Subsidiaries and Affiliates in Company’s Non-consolidated Financial Statements (Japanese GAAP)
  • Sumitomo Pharma Announces Establishment of Trading Company in China
  • Sumitomo Pharma Contributes to the Earthquake Relief Efforts in Eastern Taiwan
  • Sumitomo Pharma Announces Sale of Strategic Shareholdings
  • Initiation of Company-sponsored Clinical Study on iPS Cell-derived Dopaminergic Progenitor Cells for Parkinson’s Disease in the United States
  • Sumitomo Pharma Announces Transfer of Equities of its Consolidated Subsidiary in the U.S.
  • Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka
  • Sumitomo Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
  • Sumitomo Pharma Announces Reduction of Workforce and Other Rationalization Measures of the USA Consolidated Subsidiary
  • Posted Conference on Q3 FY2023 Financial Results [Webcast]
  • Presentation Material (Conference on Q3 FY2023 Financial Results)
  • Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2024
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2024 [IFRS]
  • Sumitomo Pharma Announces Revisions to Its Financial Forecasts
  • Notice Concerning Finance Income
  • Posting of Business Structure Improvement Expenses
  • Sumitomo Pharma Contributes to the 2024 Noto Peninsula Earthquake Relief Efforts in Japan
  • Start of Investigator-Initiated Clinical Study of iPS Cell-Derived Dopaminergic Progenitor Cells for Parkinson’s Disease in the United States
  • Sumitomo Pharma Announces Personnel Change
  • Sumitomo Pharma Presents Encouraging New Data on DSP-5336 Clinical Activity at the American Society of Hematology Annual Meeting
  • Posted Fact Book 2023 ver.2
  • Sumitomo Pharma Announces the Approval of XENLETA (lefamulin acetate) for the Treatment of Community-Acquired Pneumonia in China
  • Sumitomo Pharma and ORIX Eco Services to Collaborate on Recycling Blister Packaging Waste at Suzuka Plant
  • Sumitomo Pharma Receives SBTi (Science Based Targets initiative) Approval
  • Posted Video of Conference on Q2 FY2023 Financial Results [Webcast]
  • Sumitomo Pharma America to Present Preliminary Clinical Data Evaluating Investigational Oncology Agents TP-3654 and DSP-5336 at the American Society of Hematology Annual Meeting
  • Presentation Material (Conference on Q2 FY2023 Financial Results)
  • Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2024
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2024 [IFRS]
  • Notice Concerning Finance Income
  • Posting of Business Structure Improvement Expenses
  • AlphaNavi Pharma Exercises Option Regarding DSP-3905 under Development for Neuropathic Pain
  • Sumitomo Pharma Announces Authorization in Canada of ORGOVYX (relugolix) for the Treatment of Men with Advanced Prostate Cancer
  • Posted Integrated Report 2023
  • Sumitomo Pharma and Pfizer in Canada Receive Health Canada Approval for MYFEMBREE
  • Sumitomo Pharma Announces Personnel Change
  • GHIT Fund Awards Grant for Development of New Vaccine to Prevent Clinical Malaria by Ehime University and Sumitomo Pharma
  • Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia
  • Sumitomo Pharma Announces Change of European Consolidated Subsidiary’s Trade Name
  • Sumitomo Pharma Selected for Five Inclusions as a Constituent of GPIF-Adopted ESG Indexes
  • Posted Conference on Q1 FY2023 Financial Results [Webcast]
  • Presentation Material (Conference on Q1 FY2023 Financial Results)
  • Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2024
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2024 [IFRS]
  • Notice Concerning Finance Income
  • Posting of Business Structure Improvement Expenses
  • Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 DIAMOND 1 and DIAMOND 2 Clinical Studies Evaluating Ulotaront in Schizophrenia
  • Elucidation of the Mode of Action of Novel Universal Influenza Vaccine Candidates
  • Sumitomo Pharma America Launches as New Combined Organization with Expanded Scale, Resources & Capabilities
  • Sumitomo Pharma Announces Changes in Executive Officers
  • Consolidated Financial Statements for Years ended March 31, 2023 and 2022
  • Posted Fact Book 2023
  • Start of Phase 1/2 Study of Allogeneic iPS Cell-Derived Retinal Pigment Epithelial Cells
  • Sumitomo Pharma Announces Change in Name of Wholly Owned Subsidiary Companies
  • Joint Research between The Kitasato Institute and Sumitomo Pharma Data on KSP-1007/Meropenem for the Treatment of Carbapenem-Resistant Infections, Presented at the American Society for Microbiology (ASM) Microbe 2023
  • Sumitomo Pharma Launches Operation of a Chat Tool Using Generative AI in its Dedicated Environment
  • Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress
  • Generation and purification of ACTH-secreting hPSC-derived pituitary cells for effective transplantation
  • Sumitomo Pharma Announces Changes in the Positions Assumed by Executive Officers and Other Key Positions
  • Sumitomo Pharma Announces Completion of Share Transfer of Consolidated Subsidiary, Sumitomo Pharma Animal Health
  • Posted Notice of Convocation of the 203rd Annual Shareholders' Meeting
  • Submission of clinical trial notification for RPE tear using RPE cells derived from allogeneic iPS cells (HLCR011)
  • Posted Investors Meeting Presentation for FY2022 (Year ended March 31, 2023) [Webcast]
  • Investors Meeting Presentation for FY2022 (Year ended March 31, 2023)
  • Supplementary Financial Data (IFRS) for the Year Ended March 31, 2023
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2023 [IFRS]
  • Sumitomo Pharma Announces Changes in Audit & Supervisory Board and Other Key Position
  • Posted Video of Mid-term Business Plan 2027 Presentation [Webcast]
  • Presentation Material (Mid-term Business Plan 2027)
  • Sumitomo Pharma Announces Mid-term Business Plan 2027 (FY2023-FY2027)
  • Announcement of Dividend Forecast for the Year Ending March 31, 2024, and Reduction in Executive Remuneration
  • Sumitomo Pharma Announces Revisions to Its Financial Forecasts
  • Notice Concerning Finance Income
  • Notification of Valuation Loss on Shares of Subsidiaries and Affiliates in Company’s Non-consolidated Financial Statements (Japanese GAAP)
  • Sumitomo Pharma Redesigns Corporate Website
  • MHLW Grants Priority Review to Support Program for Screening of Depression / Rating of Severity "SWIFT" (tentative name) as First Software as a Medical Device (SaMD)
  • JCR and Sumitomo Pharma Enter into Co-Promotion Agreement in Japan for IZCARGO I.V. Infusion 10 mg, a Recombinant Therapeutic for Mucopolysaccharidosis Type II
  • Sumitomo Pharma Announces the Combination of Group Companies in the U.S.
  • Sumitomo Pharma Announces Completion of Share Transfer of Consolidated Subsidiary, Sumitomo Pharma Food & Chemical
  • Sumitomo Pharma and National Center for Global Health and Medicine Initiate 2nd Joint International Project on Measures against Antimicrobial Resistance (AMR) and Promoting Proper Use of Antibiotics in Vietnam
  • Sumitomo Pharma, Sumitovant Biopharma, and Myovant Sciences Complete the Transaction
  • KYORIN and Sumitomo Pharma Enter into License Agreement of Vibegron in Taiwan and Other Asian Countries
  • Announcement on Impairment Loss and Revision of Dividend Forecast
  • Sumitomo Pharma Announces Organizational Realignment and Changes in the Positions Assumed by Executive Officers and Other Key Positions
  • Sumitomo Pharma Announces Contributes to the Relief Efforts for the Earthquake in Turkey and Syria
  • Presentation Material（Third Quarter Financial Results for FY2022）
  • Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2023
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2023 [IFRS]
  • Sumitomo Pharma Announces Revisions to Its Financial Forecasts
  • Notice Concerning Finance Costs
  • Sumitomo Pharma Announces Transfer of Shares of a Consolidated Subsidiary, Sumitomo Pharma Animal Health
  • Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
  • Sumitomo Pharma Announces Divestiture of LUNESTA to Woodward Pharma Services LLC
  • ESG Meeting Presentation (Discussion with Investors)
  • Enzyvant Announces Merger with Altavant
  • Posted Factbook 2022 ver.2
  • Sumitomo Pharma Announces Transfer of Shares of a Consolidated Subsidiary, Sumitomo Pharma Food & Chemical
  • GARDP and Sumitomo Pharma announce partnership in search for new antibiotics
  • Posted Video of Investors Meeting Presentation for Q2 FY2022 [Webcast]
  • Investors Meeting Presentation for Q2 FY2022 (April 1 to September 30, 2022)
  • Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2023
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2023 [IFRS]
  • Sumitomo Pharma Announces Revisions to Its Financial Forecasts
  • Notice Concerning Finance Income
  • Sumitomo Pharma, Sumitovant Biopharma, and Myovant Sciences Enter into Definitive Agreement
  • Sumitomo Pharma Announces Intent to Divest Brovana and Xopenex HFA to Lupin
  • Sumitomo Pharma Announces Posting Impairment Loss
  • Sumitomo Pharma and Sumitovant Biopharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
  • Sumitomo Pharma and MELTIN Enter into Marketing Alliance for MELTz Hand Rehabilitation System and Launch It
  • Joint Research between The Kitasato Institute and Sumitomo Pharma: Drug Combination of Meropenem and KSP-1007 for Treatment of Carbapenem-Resistant Bacteria Infections Designated as Qualified Infectious Disease Product (QIDP)/Fast Track
  • Appeal of Inter Partes Review (IPR) USPTO Decision on the Method of Use Patent for LATUDA
  • Posted Integrated Report 2022
  • Sumitomo Pharma Announces Personnel Changes
  • Sumitomo Pharma Selected for Inclusion as a Constituent of Five GPIF-Adopted ESG Indexes that Cover Japanese Stocks
  • Myovant Sciences and Pfizer Receive U.S. FDA Approval of MYFEMBREE, a Once-Daily Treatment for the Management of Moderate to Severe Pain Associated With Endometriosis
  • Posted Conference Call for Q1 FY2022 [Webcast]
  • Notice of conclusion of sales collaboration for GLP-1 receptor agonist "Trulicity Subcutaneous Injection 0.75 mg Ateos"
  • Presentation Material（First Quarter Financial Results for FY2022）
  • Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2023
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2023 [IFRS]
  • Notice Concerning Finance Income
  • Notice of Relocation of Tokyo Head Office
  • Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland
  • Consolidated Financial Statements for Years ended March 31, 2022 and 2021
  • Posted Fact Book 2022
  • (Update on Disclosed Matter) Notice of Establishment of Holding Company in China
  • Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE
  • Posted Notice of Convocation of the 202nd Annual Shareholders' Meeting
  • Posted Video of Investors Meeting Presentation for FY2021 [Webcast]
  • Investors Meeting Presentation for FY2021 (Year ended March 31, 2022)
  • Supplementary Financial Data (IFRS) for the Year Ended March 31, 2022
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2022 [IFRS]
  • Sumitomo Pharma Announces Changes in Board of Directors and Audit & Supervisory Board
  • Myovant Sciences and Accord Healthcare, Ltd. Enter into Exclusive License Agreement to Commercialize ORGOVYX for Advanced Hormone-Sensitive Prostate Cancer in Europe
  • Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application (sNDA) for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis
  • Sumitomo Pharma and Jazz Pharmaceuticals Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
  • Myovant Sciences Announces European Commission Approval for ORGOVYX (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer
  • Sumitomo Pharma Announces Revisions to Its Financial Forecasts
  • Sumitomo Pharma Builds Cell-Processing Center in U.S.
  • Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE for the Management of Moderate to Severe Pain Associated with Endometriosis
  • Switch to 100% Renewable Energy for Electric Power Purchased by Suzuka Plant
  • Notification of Valuation Loss on Investment Securities Recorded in Company's Non-consolidated Financial Statements (Japanese GAAP)
  • Notice of Change of the Trade Name
  • National Cancer Center Japan, Shonai Regional Industry Promotion Center and Sumitomo Dainippon Pharma Announce Start of Phase 1/2 Study on New Drug Candidate Compound in Acute Myeloid Leukemia
  • Notice of Establishment of Holding Company in China
  • Sumitomo Dainippon Pharma Provides Material Assistance to Ukraine
  • Sumitomo Dainippon Pharma Enacts Basic Policy for Respecting Human Rights
  • Sumitomo Dainippon Pharma Announces Additional Investment in Aikomi Ltd.
  • Sumitomo Chemical Announces the New Corporate Business Plan FY2022 - FY2024
  • Sumitomo Dainippon Pharma Announces Changes in Executive Officers Including Representative Director, Organizational Realignment and Personnel Changes
  • JCR and Sumitomo Dainippon Pharma Enter into Marketing Alliance for Agalsidase Beta BS I.V. Infusion [JCR], for Treatment of Fabry Disease in Japan
  • Myovant Sciences Receives Positive CHMP Opinion for ORGOVYX (relugolix) for the Treatment of Advanced Prostate Cancer
  • Posted Conference Call for Q3 FY2021 [Webcast]
  • Presentation Material（Third Quarter Financial Results for FY2021）
  • Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2022
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2022 [IFRS]
  • Kitasato Institute and Sumitomo Dainippon Pharma Start Phase 1 Study on New Drug Candidate Compound Discovered in Joint Research as Treatment for Carbapenem-resistant Bacterial Infections
  • Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
  • Sumitomo Dainippon Pharma Announces Phase 3 Study of Investigational Cancer Vaccine DSP-7888 in Patients with Glioblastoma Terminates
  • Notice of the Decision of USPTO on Inter Partes Review (IPR) Proceeding for Method of Use Patent of LATUDA
  • ESG Meeting (Discussion with Investors)
  • Sumitomo Dainippon Pharma Establishes a Local Subsidiary in Malaysia
  • Posted Integrated Report 2021
  • Notice of Application for Selection of "Prime Market" in Tokyo Stock Exchange New Market Segments
  • Posted Factbook 2021 ver.2
  • Succession of Manufacturing and Marketing Approval and Marketing Rights of REPLAGAL 3.5 mg for Fabry Disease, an α-Galactosidase Enzyme IV Infusion
  • Sumitomo Dainippon Pharma Receives the Gold Rating in the PRIDE Index for Initiatives Related to LGBTQ for the Second Consecutive Year
  • Posted Video of Investors Meeting Presentation for Q2 FY2021 [Webcast]
  • Sumitomo Dainippon Pharma Announces Support for the Recommendations of the Task Force on Climate-related Financial Disclosures (TCFD)
  • Investors Meeting Presentation for Q2 FY2021 (April 1 to September 30, 2021）
  • Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2022
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2022 [IFRS]
  • Sumitomo Dainippon Pharma and BehaVR announce landmark deal for multiple virtual reality digital therapeutics
  • Enzyvant Receives FDA Approval for RETHYMIC (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
  • Sumitomo Dainippon Pharma and Otsuka Announce a Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds
  • Posted Video of Frontier Business Meeting - FBO Showcase - [Webcast]
  • Sumitomo Dainippon Pharma Announces Launch of TWYMEEG for the Treatment of Type 2 Diabetes in Japan
  • Myovant Sciences and Pfizer Announce FDA Acceptance of Supplemental New Drug Application for MYFEMBREE for the Management of Moderate to Severe Pain Associated With Endometriosis
  • Posted Presentation Material (Frontier Business Meeting - FBO Showcase -)
  • Sumitomo Dainippon Pharma and Pixie Dust Technologies Sign Joint R&D Agreement on Communication Support Smart Glasses for Hard of Hearing People
  • Sunovion and BIAL Enter European Licensing Agreement for Apomorphine Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
  • Sumitomo Dainippon Pharma Opens a Representative Office in Vietnam
  • Sumitomo Dainippon Pharma Announces Personnel Changes
  • Sumitomo Dainippon Pharma Announces Transfer of Shares of its Indirectly-Owned Subsidiary in Europe
  • Sumitomo Dainippon Pharma Listed Continuously in FTSE4Good Index Series and FTSE Blossom Japan Index of ESG Indices
  • Posted Conference Call for Q1 FY2021 [Webcast]
  • Presentation Material（First Quarter Financial Results for FY2021）
  • Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2022
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2022 [IFRS]
  • Myovant Sciences Announces European Commission Approval for RYEQO for the Treatment of Women With Uterine Fibroids
  • Posted Factbook 2021
  • Sumitomo Dainippon Pharma Announces Release of Movie on Change of Company Name
  • Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan
  • Chemiphar and Sumitomo Dainippon Pharma Conclude Collaborative Research and Development Agreement and Option Agreement for Novel Antidepressant/Anxiolytic Candidate Compound "NC-2800"
  • Comments Regarding Media Article on Our Company
  • Myovant Sciences and Pfizer Receive FDA Approval for MYFEMBREE, the First Once-Daily Treatment for Heavy Menstrual Bleeding Associated With Uterine Fibroids
  • Posted Notice of Convocation of the 201th Annual Shareholders' Meeting
  • Myovant Sciences Receives Positive CHMP Opinion for RYEQO (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids
  • Posted Video of Investors Meeting Presentation for FY2020 (Year ended March 31, 2021) and Revision of Mid-term Business Plan 2022 [Webcast]
  • Investors Meeting Presentation for FY2020 (Year ended March 31, 2021) and Revision of Mid-term Business Plan 2022
  • Supplementary Financial Data (IFRS) for the Year Ended March 31, 2021
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2021 [IFRS]
  • Sumitomo Dainippon Pharma Announces Revised Mid-term Business Plan 2022 (FY2018-FY2022)
  • Notice of Change of Trade Name and Partial Amendment to Articles of Incorporation
  • Notice of Relocation of Tokyo Head Office
  • Sumitomo Dainippon Pharma Announces Changes in Board of Directors and Audit & Supervisory Board
  • Sumitomo Dainippon Pharma Revises Its Basic Environmental Policies
  • Sumitomo Dainippon Pharma Announces Acquisition of Rights for Certain Sinovant Development Compounds in China and Other Asian Countries
  • Consolidated Subsidiary Enzyvant Transfers its RVT-801, an Investigational Therapy for Farber Disease, to Aceragen
  • Sumitomo Dainippon Pharma Announces Investment in Special Purpose Acquisition Company Combining with Roivant Sciences
  • ENZYVANT Resubmits Biologics Licensing Application (BLA) to FDA for RVT-802 for Pediatric Congenital Athymia
  • Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
  • Urovant Sciences Announces U.S. Commercial Launch of GEMTESA (vibegron) 75 mg Tablets for Patients with Overactive Bladder
  • Sumitomo Dainippon Pharma Receives the "Intellectual Property Achievement Awards" for the First Time
  • The GHIT Fund Awards Grant for the Development of a New Malaria Pre-erythrocytic Vaccine
  • Sumitovant Completes the "Going Private" Transaction with Our Consolidated Subsidiary, Urovant
  • Myovant Sciences Announces European Medicines Agency Validation of Marketing Authorization Application for Relugolix for the Treatment of Advanced Prostate Cancer
  • Posted Video of Sumitovant Meeting [Webcast]
  • Sumitomo Dainippon Pharma Announces the Launch of Website Dedicated to Frontier Business
  • Posted Presentation Material (Sumitovant Meeting)
  • Sumitomo Dainippon Pharma Announces Posting of Impairment Loss
  • Sumitomo Dainippon Pharma Earns Recognition for the First Time in the Health & Productivity Management Stock Selection
  • Sumitomo Dainippon Pharma Announces Organizational Realignment and Changes in the Positions Assumed by Executive Officers and Other Key Positions
  • Sumitomo Dainippon Pharma Announces Changes of Representative Directors and Executive Officers
  • Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
  • Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
  • Sumitomo Dainippon Pharma Announces Topline Results of Phase 3 Study on Investigational Anti-Cancer Agent Napabucasin Fails to Reach Primary Endpoints in Patients with Colorectal Cancer
  • Posted Conference Call for Q3 FY2020 [Webcast]
  • Sumitomo Dainippon Pharma Announces Investment in a Venture Capital Fund
  • Presentation Material（Third Quarter Financial Results for FY2020）
  • Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2021
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2021 [IFRS]
  • Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
  • Myovant Sciences Announces U.S. Availability of ORGOVYX for the Treatment of Advanced Prostate Cancer
  • Consolidated Subsidiary Myovant and Pfizer Enter Into Collaboration to Develop and Commercialize Relugolix
  • Sumitomo Dainippon Pharma Concludes Positive Impact Finance Agreement with Sumitomo Mitsui Trust Bank
  • Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
  • Urovant Sciences Announces U.S. FDA Approval of GEMTESA (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
  • Myovant Sciences Announces FDA Approval of ORGOVYX (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
  • ESG Meeting (Discussion with Investors)
  • Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
  • Posted Factbook 2020 ver.2
  • Sumitovant Enters into an Agreement for "Going Private" Transaction with its U.S. Subsidiary Urovant
  • Posted Video of Investors Meeting Presentation for Q2 FY2020 [Webcast]
  • Investors Meeting Presentation for Q2 FY2020 (April 1 to September 30, 2020）
  • Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2021
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2021 [IFRS]
  • Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
  • Joint Research and Development Agreement with Drawbridge Health, Inc. on Innovative Blood Sampling Solution for Lifestyle Diseases
  • Sumitomo Chemical and Sumitomo Dainippon Pharma Announce Establishment and Inception of Operations of a Joint Venture Company for CDMO Business in the field of Regenerative Medicine and Cell Therapy
  • Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
  • Sunovion Announces the Commercial Launch of KYNMOBI (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
  • Myovant Sciences Announces Results of Additional Secondary Endpoint of Castration Resistance-Free Survival from Phase 3 HERO Study of Relugolix in Advanced Prostate Cancer
  • Posted Integrated Report 2020
  • Sumitomo Dainippon Pharma Establishes a Subsidiary in Taiwan
  • Sumitomo Dainippon Pharma and KDDI Announce Start of Initiatives to Create New Platform for Communication between MRs and HealthCare Professionals Using XR
  • Sumitomo Dainippon Pharma Announces Change in Executive Officer
  • Sumitomo Dainippon Pharma Determines Issuance Conditions for Publicly Offered Hybrid Bonds (Subordinated Bonds)
  • Sumitomo Dainippon Pharma Announces Organizational Realignment and Change in Executive Officer
  • Myovant Sciences Announces FDA Acceptance of New Drug Application for Once-Daily Relugolix Combination Tablet for Uterine Fibroids
  • Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
  • Sumitomo Dainippon Pharma, Sompo Japan, and Aikomi Announce Collaboration on R&D and Commercialization of Digital Devices for Dementia and Nursing Care
  • Posted Conference Call for Q1 FY2020 [Webcast]
  • Save Medical and Sumitomo Dainippon Pharma Announce Signing of Joint Development Agreement for Mobile App for Management of Type 2 Diabetes and Commencement of Clinical Study
  • Sumitomo Dainippon Pharma Submits New Drug Application for Approval of Manufacturing and Marketing for Imeglimin Hydrochloride for the Treatment of Type 2 Diabetes in Japan
  • Presentation Material（First Quarter Financial Results for FY2020）
  • Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2021
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2021[IFRS]
  • Sumitomo Dainippon Pharma Announces Issuance of Publicly Offered Hybrid Bonds (Subordinated Bonds)
  • Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment
  • Sumitomo Dainippon Pharma Contributes to the Relief Efforts for the Heavy Rain Event of July 2020 in Japan
  • Sunovion Announces Topline Results from Global Phase 2 Study of SEP-4199 in Patients with Bipolar I Depression
  • Posted Factbook 2020
  • Sumitomo Dainippon Pharma Announces Transfer of a Fixed Asset
  • Myovant Sciences Announces Positive Results from Second Phase 3 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis
  • Myovant Sciences Announces Priority Review and FDA Acceptance of New Drug Application for Once-Daily, Oral Relugolix for Advanced Prostate Cancer
  • Notice of the Filing of a Petition for Inter Partes Review (IPR) to USPTO for Method of Use Patent of LATUDA
  • Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
  • Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson's Disease OFF Episodes
  • Sumitomo Dainippon Pharma Announces Launch of Atypical Antipsychotic Agent, LATUDA Tablets in Japan
  • Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
  • Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine
  • Sumitomo Dainippon Pharma Announces Merger of US consolidated subsidiaries
  • Posted Notice of Convocation of the 200th Annual Shareholders' Meeting
  • Sunovion Announces U.S. FDA Approval of KYNMOBI (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson's Disease OFF Episodes
  • Posted Video of Investors Meeting Presentation for FY2019 (Year ended March 31, 2020) [Webcast]
  • Investors Meeting Presentation for FY2019 (Year ended March 31, 2020)
  • Supplementary Financial Data (IFRS) for the Year Ended March 31, 2020
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2020 [IFRS]
  • Sumitomo Dainippon Pharma Announces Change in Board of Directors
  • Sumitomo Dainippon Pharma Revises Financial Forecasts
  • Donation of Medical Protective Equipment (Face Shields, Masks and Gowns) to Support Measures against Coronavirus Disease 2019 (COVID-19)
  • Supplementary Material (Sumitomo Dainippon Pharma and National Institutes of Biomedical Innovation, Health and Nutrition Conclude Joint Research Agreement for Universal Influenza Vaccine)
  • Sumitomo Dainippon Pharma and National Institutes of Biomedical Innovation, Health and Nutrition Conclude Joint Research Agreement for Universal Influenza Vaccine
  • Myovant Sciences Announces Positive Results from Phase 3 SPIRIT 2 Study Evaluating Once-Daily Relugolix Combination Therapy in Women with Endometriosis and from Ovulation Inhibition Study
  • Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer
  • New England Journal of Medicine Publishes Pivotal Results Evaluating Sunovion's SEP-363856 for the Treatment of Schizophrenia
  • The GHIT Fund Awards Grant for the Development of a New Malaria Transmission-Blocking Vaccine by Ehime University and Sumitomo Dainippon Pharma
  • Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.
  • Donations to the Kitasato Institute's Project for COVID-19 for Early Identification of Therapeutic Medicine for its Treatment
  • Sumitomo Dainippon Pharma Announces the Approval of RETHIO for an Additional Indication of Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
  • Sumitomo Dainippon Pharma Announces Approval of Atypical Antipsychotic Agent, LATUDA Tablets in Japan
  • Sumitomo Dainippon Pharma Announces Change in Executive Officer and Other Key Position
  • Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
  • Posted Video of R&D Meeting [Webcast]
  • Urovant Sciences Announces U.S. FDA Acceptance of New Drug Application for Vibegron for the Treatment of Overactive Bladder
  • Posted Presentation Material (R&D Meeting)
  • Sumitomo Dainippon Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
  • Sumitomo Dainippon Pharma Announces Investment in MPM Oncology Innovations Fund
  • Posted Conference Call for Q3 FY2019 [Webcast]
  • Announcement of Borrowing Funds
  • Presentation Material (Third Quarter Financial Results for FY2019)
  • Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2020
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2020 [IFRS]
  • Sumitomo Dainippon Pharma and Exscientia Joint Development　New Drug Candidate Created Using Artificial Intelligence (AI) Begins Clinical Study
  • Donations for the Prevention of Pneumonia Caused by the New Coronavirus in China
  • Sumitomo Dainippon Pharma announces Personnel Change
  • Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life‐Saving Treatment for Post‐Lung Transplant Patients to the Altavant Pipeline
  • Urovant Sciences Announces Submission of New Drug Application for Vibegron for the Treatment of Overactive Bladder
  • Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences
  • Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film
  • Poxel and Sumitomo Dainippon Pharma Announce Positive Topline Phase 3 Results from TIMES 2 Trial of Imeglimin for the Treatment of Type 2 Diabetes in Japan and Successful Completion of the Pivotal TIMES Clinical Development Program
  • SanBio and Sumitomo Dainippon Pharma Announce a Termination of a Joint Development and License Agreement for Regenerative Cell Medicine SB623 for Chronic Stroke in North America
  • Boston Biomedical, Inc. Enters into an Alliance in Oncology Research with Columbia University, Harvard University and The Wistar Institute
  • Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
  • Posted Factbook 2019 ver.2
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officer and Other Key Positions
  • ESG Meeting (Discussion with Investors)
  • Sunovion Resubmits New Drug Application for Apomorphine Sublingual Film
  • iPS Cell Research Discovers Common Pathologies in Psychiatric Disorders Elucidation of the Pathogenesis of Bipolar Disorder and Schizophrenia May Find Application in Therapeutic Drug Development
  • Posted Video of Investors Meeting Presentation for Q2 FY2019 (April 1 to September 30, 2019) ／Definitive Agreement for Strategic Alliance with Roivant Sciences [Webcast]
  • Press Conference Presentation for Definitive Agreement for Strategic Alliance with Roivant Sciences
  • Investors Meeting Presentation for Q2 FY2019 (April 1 to September 30, 2019) ／Definitive Agreement for Strategic Alliance with Roivant Sciences
  • Press Conference Presentation for Definitive Agreement for Strategic Alliance with Roivant Sciences
  • Sumitomo Dainippon Pharma and Roivant Sciences Sign a Definitive Agreement for a Strategic Alliance
  • 【Joint press release】Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
  • Press Conference Presentation for Q2 FY2019 (April 1 to September 30, 2019)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2020
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2020
  • Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the half-year period ending September 30, 2019
  • Sumitomo Dainippon Pharma Contributes to the Typhoon Hagibis in October 2019 in Japan
  • Sumitomo Dainippon Pharma announces Change in Executive Officer
  • Comments on Acquisition Proposal to Australian Stem Cell and Regenerative Medicine Company
  • Posted Integrated Report 2019
  • Posted Conference Call for Memorandum of Understanding for Strategic Alliance with Roivant Sciences [Webcast]
  • Presentation Material（Memorandum of Understanding for Strategic Alliance with Roivant Sciences）
  • Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding for a Strategic Alliance
  • 【Joint press release】Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients
  • Sumitomo Dainippon Pharma to Launch Atypical Antipsychotic LONASEN Tape in Japan
  • Sumitomo Dainippon Pharma Announces the Launch of Atypical Antipsychotic LATUDA in China
  • Sumitomo Dainippon Pharma announces Investment in a Venture Capital Fund
  • Posted Conference Call for Q1 FY2019 [Webcast]
  • Sumitomo Dainippon Pharma Submits New Drug Application for Approval of Manufacturing and Marketing for Lurasidone in Japan for the Treatment of Schizophrenia and Bipolar Depression
  • Sunovion Announces Acceptance by the U.S. FDA of the New Drug Application for Dasotraline for the Treatment of Adults with Moderate-to-Severe Binge Eating Disorder
  • Presentation Material (First Quarter Financial Results for FY2019)
  • Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2020
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2020 [IFRS]
  • Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
  • Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment and FTSE Blossom Japan Index
  • Sumitomo Dainippon Pharma to Enter Into an Investment Agreement with Drawbridge Health
  • Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Clinical Study of LONASEN, an Atypical Antipsychotic Agent, in the Treatment of Adolescent Patients with Schizophrenia in Japan
  • Comments on Announcement by Australian Stem Cell and Regenerative Medicine Company
  • Sumitomo Dainippon Pharma and National Center for Global Health and Medicine Initiate International Project on Measures against Antimicrobial Resistance (AMR) and Promote the Proper Use of Antibiotics in Vietnam
  • Sumitomo Dainippon Pharma Announces Discontinuation of Phase 3 CanStem111P Study of Investigational Anti-Cancer Agent Napabucasin in Patients with Pancreatic Cancer Following Interim Analysis
  • Posted FactBook 2019
  • Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 3) in Japan for the Treatment of Type 2 Diabetes
  • Sumitomo Dainippon Pharma and Nitto Denko Announce the Approval of Atypical Antipsychotic LONASEN Tape in Japan
  • Sumitomo Dainippon Pharma announces Personnel Changes
  • Sumitomo Dainippon Pharma announces Changes to Agreement on Joint Development of Treatments for Eye Diseases Using iPS Cell-derived Retinal Pigment Epithelial Cells in Japan
  • Sumitomo Dainippon Pharma Announces Recommendation to Continue Phase 3 CanStem303C Study of Investigational Anti-Cancer Agent Napabucasin in Patients with Colorectal Cancer Following Interim Analysis
  • Sumitomo Dainippon Pharma Signs a Co-Promotion and Sales Collaboration Agreement for Diabetes Treatments Equa and EquMet in Japan
  • Posted Notice of Convocation of the 199th Annual Shareholders' Meeting
  • Sumitomo Dainippon Pharma to Launch RETHIO for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation
  • Posted Video of Investors Meeting Presentation for FY2018 [Webcast]
  • Presentation Material (Financial Results for FY2018)
  • Supplementary Financial Data (IFRS) for the Year Ended March 31, 2019
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2019 [IFRS]
  • Sumitomo Dainippon Pharma announces Changes in Board of Directors
  • Sunovion and PsychoGenics Announce that SEP-363856 Has Received FDA Breakthrough Therapy Designation for the Treatment of People with Schizophrenia
  • Sumitomo Dainippon Pharma to Open a New Office for its Regenerative Medicine/Cell Therapy Business in San Diego, U.S.
  • Sumitomo Dainippon Pharma Announces Revision to its Dividend Forecast for the Year Ending March 2019
  • Sumitomo Dainippon Pharma Revises Financial Forecasts
  • Posted Video of Mid-term Business Plan 2022 [Webcast]
  • Presentation Material (Mid-term Business Plan 2022)
  • Sumitomo Dainippon Pharma Announces Mid-term Business Plan 2022(FY2018 - FY2022)
  • Poxel and Sumitomo Dainippon Pharma Announce Positive Top-Line Results for Imeglimin Phase 3 Trial (TIMES 1) in Japan for the Treatment of Type 2 Diabetes
  • GHIT Fund Awards Grant for Continuing Development of Malaria Vaccine Discovered by Ehime University and Sumitomo Dainippon Pharma
  • Five Partners Commence Joint R&D on Renal Regenerative Medicine
  • Sumitomo Dainippon Pharma Submits an Application of RETHIO for an Additional Indication of Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Malignant Lymphoma
  • AlphaNavi Pharma Established as a Carve-Out Business Venture from Sumitomo Dainippon Pharma with Investment
  • Sumitomo Dainippon Pharma Receives Approval in Japan for RETHIO for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation
  • Sumitomo Chemical Announces the New Corporate Business Plan FY2019 - FY2021
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
  • Sumitomo Dainippon Pharma Expands Roles and Responsibilities of Subsidiary in Singapore and Establishes Subsidiary in Thailand
  • Sumitomo Dainippon Pharma and Aikomi Conclude Joint Research Agreement on Medical Devices to Relieve Behavioral and Psychological Symptoms of Dementia
  • Posted Conference Call for Q3 FY2018 [Webcast]
  • Presentation Material (Third Quarter Financial Results for FY2018)
  • Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2019
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2019 [IFRS]
  • Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
  • Sumitomo Dainippon Pharma Announces the Approval of Atypical Antipsychotic Latuda (lurasidone HCl) for the Treatment of Patients with Schizophrenia in China
  • SanBio and Sumitomo Dainippon Pharma Announce Topline Results from a Phase 2b Study in the U.S. Evaluating SB623, a Regenerative Cell Medicine for the Treatment of Patients with Chronic Stroke
  • Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase III Clinical Study (JEWEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
  • Correction to "Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S."
  • Merger of DS Pharma Biomedical and DS Pharma Promo
  • Kyoto University's Center for iPS Cell Research and Application, Sumitomo Chemical, and Sumitomo Dainippon Pharma Commence Joint Research on Producing Higher-Quality iPS Cells for Clinical Use
  • Sumitomo Dainippon Pharma Announces Resolution of Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S.
  • Posted Factbook 2018 ver.2
  • Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S. (Partial correction on December 28, 2018)
  • Posted Video of ESG Meeting (Discussion with Investors) [Webcast]
  • ESG Meeting (Discussion with Investors)
  • Announcement of the establishment of new joint company by Sumitomo Bakelite Co., Ltd. and Sumitomo Dainippon Pharma Co., Ltd.
  • Posted Video of Investors Meeting Presentation for Q2 FY2018 [Webcast]
  • Sumitomo Dainippon Pharma announces the Clinical Data of Investigational Anti-Cancer Agent Alvocidib will be presented at ASH 2018
  • Investors Meeting Presentation for Q2 FY2018
  • Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2019
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2019 [IFRS]
  • Sumitomo Dainippon Pharma to Invest in and Start Joint Research and Development with MELTIN
  • Posted Integrated Report 2018
  • Sumitomo Dainippon Pharma Receives the Award of Gold Class in Overall Category of SUSTAINA ESG AWARD 2018
  • Sumitomo Dainippon Pharma Selected as a Component of Dow Jones Sustainability Indices (DJSI) for the second Consecutive Year
  • Sumitomo Dainippon Pharma Contributes to the 2018 Hokkaido Eastern Iburi Earthquake Relief Efforts in Japan
  • Results of Phase 3 Studies Evaluating Patch Formulation of Atypical Antipsychotic LONASEN Presented at Congress
  • Sumitomo Dainippon Pharma announces personnel changes
  • FDA Issues a Complete Response Letter for New Drug Application for Dasotraline for the Treatment of ADHD
  • Posted Conference Call for Q1 FY2018 [Webcast]
  • New Drug Application in Japan for Transdermal Patch Formulation of Atypical Antipsychotic LONASEN
  • Kyoto University Hospital and the Center for iPS Cell Research and Application (CiRA) to begin Physician-initiated Clinical Trials for Parkinson's Disease that Transplants Dopamine progenitor cells generated from Induced Pluripotent Stem (iPS) Cells
  • Presentation Material (First Quarter Financial Results for FY2018)
  • Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2019
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2019 [IFRS]
  • Sunovion Announces Positive Top-Line Results from Pivotal Study Evaluating Dasotraline in Adults with Binge Eating Disorder
  • Sumitomo Dainippon Pharma Contributes to the Relief Efforts for the Heavy Rain Event of July 2018 in Japan
  • Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment and FTSE Blossom Japan Index
  • Sumitomo Dainippon Pharma Submits New Drug Application for Thiotepa in Japan for Conditioning Treatment Prior to Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors
  • Posted FactBook 2018
  • Sumitomo Dainippon Pharma Obtains Approval in Japan for TRERIEF, a therapeutic agent for Parkinson's disease, for an Additional Indication of Parkinsonism in Dementia with Lewy Bodies
  • Sumitomo Dainippon Pharma Contributes to Northern Osaka Earthquake Relief Efforts in Japan
  • Sunovion Presents Data from Pivotal Phase 3 Study of Apomorphine Sublingual Film (APL-130277) at the 2nd Pan American Parkinson's Disease and Movement Disorders Congress
  • Sumitomo Dainippon Pharma announces personnel changes
  • Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)
  • Sumitomo Dainippon Pharma Joins IFPMA as New Member
  • Posted Notice of Convocation of the 198th Annual Shareholders' Meeting
  • Sumitomo Dainippon Pharma announces the Clinical Data of Investigational Anti-Cancer Agent Alvocidib will be presented at EHA2018
  • Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2018
  • Posted Video of Financial Results for FY2017 [Webcast]
  • Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions
  • Presentation Material (Financial Results for FY2017)
  • Supplementary Financial Data for the Year Ended March 31, 2018
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2018 [IFRS]
  • Sumitomo Dainippon Pharma Revises Financial Forecasts (J-GAAP) and Announces Financial Forecasts under IFRS
  • Sumitomo Dainippon Pharma Announces Joint Research Agreement with MMV for Identification of Antimalarial Candidate Compounds
  • Sumitomo Dainippon Pharma Announces U.S. Appellate Court Decision on Substance Patent Infringement Lawsuit Regarding LATUDA
  • Sunovion Announces Lonhala Magnair (glycopyrrolate) Inhalation Solution Now Available in the U.S. for the Treatment of COPD
  • Posted Disclosure of Clinical Study Data
  • Sunovion Submits New Drug Application to the FDA for Apomorphine Sublingual Film (APL-130277) for the Treatment of OFF Episodes Associated with Parkinson's Disease
  • Carna Biosciences and Sumitomo Dainippon Pharma Sign Agreement on Joint Research, Development, and Commercialization of Kinase Inhibitors
  • Establishment of Shared Service Subsidiary
  • Sunovion Receives FDA Approval of Supplemental New Drug Application (sNDA) for Use of Latuda (lurasidone HCl) in the Treatment of Bipolar Depression in Pediatric Patients (10 to 17 Years of Age)
  • Updated Regenerative Medicine/Cell Therapy Business Plan
  • Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy
  • Pfizer and Sumitomo Dainippon Pharma Commence the Co-Promotion of Serotonin-Norepinephrine Reuptake Inhibitor EFFEXOR SR Capsules
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
  • Sumitomo Dainippon Pharma and JCR Sign a License Agreement on Blood-Brain Barrier Penetration Technology for Creation of a Therapeutic Agent for Central Nervous System Diseases
  • SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Additional Patent Infringement Lawsuit Regarding LATUDA in the United States
  • Sumitomo Dainippon Pharma Appoints Hiroshi Nomura as President and CEO
  • Sumitomo Dainippon Pharma Announces Amends the License Agreement for Obeticholic Acid (DSP-1747)
  • Sumitomo Dainippon Pharma and Nitto Announce Positive Topline Results from Phase 3 Study Evaluating Transdermal Patch Formulation of Atypical Antipsychotic LONASEN
  • SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Patent Infringement Lawsuits Regarding LATUDA in the United States
  • Posted Conference Call for Third Quarter Financial Results for FY2017 [Webcast]
  • Updated Disclaimer Regarding Forward-Looking Statements
  • Updated Disclaimer Regarding Forward-Looking Statements of Fact Book
  • Sumitomo Dainippon Pharma Announces an Atypical Antipsychotic LONASEN is Now Available in China
  • Sumitomo Dainippon Pharma Announces Revision to its Dividend Forecast for the Year Ending March 2018
  • Presentation Material (Third Quarter Financial Results for FY2017)
  • Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2018
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2018 [Japanese GAAP] (Unaudited)
  • Sunovion Announces Positive Topline Results from Pivotal Study of Apomorphine Sublingual Film (APL-130277) in Patients with Parkinson's Disease
  • Sumitomo Dainippon Pharma announces Personnel Change
  • Poxel and Sumitomo Dainippon Pharma Announce Initiation of Phase 3 Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan
  • Sumitomo Dainippon Pharma Announces the Results of Its Early Retirement Program Offer for Japanese Employees
  • Dissolution of Create Vaccine Company, Ltd.
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Personnel Change
  • Establishment of Bioscience Research Laboratory and Transfer of Functions of Genomic Science Laboratories
  • Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD
  • Posted Factbook 2017 ver.2
  • Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
  • Sunovion Announces FDA Acceptance for Review of New Drug Application for Dasotraline for the Treatment of ADHD
  • Posted Video of Second Quarter Financial Results for FY2017 [Webcast]
  • Sumitomo Dainippon Pharma and Poxel Announce Strategic Partnership for Development and Commercialization of Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan, China and Eleven Other Asian Countries
  • Presentation Material (Second Quarter Financial Results for FY2017)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2018
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2018 [Japanese GAAP] (Unaudited)
  • Kitasato Institute and Sumitomo Dainippon Pharma Sign a Joint Drug Discovery Research Agreement for Infections Caused by Bacteria with Antimicrobial Resistance (AMR)
  • Sunovion Announces Seebri Neohaler (glycopyrrolate) Inhalation Powder is Now Available in the United States
  • Sumitomo Dainippon Pharma announces offering an Early Retirement Program to Japanese Employees
  • Sumitomo Dainippon Pharma Announces First-ever Inclusion in Dow Jones Sustainability Indices (DJSI)
  • Posted Annual Report 2017
  • Sunovion's Aptiom (eslicarbazepine acetate) Receives FDA Approval for Expanded Indication to Treat Partial-Onset Seizures in Children and Adolescents 4 Years of Age and Older
  • Sumitomo Dainippon Pharma and Maruishi Pharmaceutical concluded a license agreement for an Antiemetic Candidate Compound
  • Sunovion Submits New Drug Application for Dasotraline to the FDA for the Treatment of Patients with ADHD
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
  • Sumitomo Dainippon Pharma Submits an Application in Japan for TRERIEF, a therapeutic agent for Parkinson's disease, for an Additional Indication of Parkinsonism in Dementia with Lewy Bodies
  • Posted Conference Call for First Quarter Financial Results for FY2017 [Webcast]
  • Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts
  • Presentation Material (First Quarter Financial Results for FY2017)
  • Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2018
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2018 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma Announces Investment in DEFTA Healthcare Technologies, L.P.
  • Sunovion Enters Agreement to Divest Asthma and Allergy Products to Covis Pharma
  • Sumitomo Dainippon Pharma Announces Change in Name of Consolidated Subsidiary Based in U.S.
  • Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for SUN-101/eFlow (glycopyrrolate) for the Treatment of Chronic Obstructive Pulmonary Disease (COPD)
  • Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment for the 15th Consecutive Year
  • Sumitomo Dainippon Pharma Announces Unblinding of Phase 3 Study of Napabucasin, a cancer stemness inhibitor, in Patients with Gastric/GEJ Cancer
  • Posted FactBook 2017
  • Sumitomo Dainippon Pharma announces personnel change
  • Sumitomo Dainippon Pharma Announces Partnership with Zuellig Pharma on its Carbapenem Antibiotic Meropenem for Five Countries of South-East Asia and Hong Kong
  • Sumitomo Dainippon Pharma Announces Topline Results from a Phase 3 Study of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Bipolar l Depression
  • Sumitomo Dainippon Pharma Contributes funding to the Global Health Innovative Technology Fund (GHIT Fund) for the Second Period
  • Toray's Pruritus Treatment REMITCH OD Tablets 2.5 μg to Be Introduced in Japan
  • Sunovion Receives Complete Response Letter from FDA for SUN-101/eFlow (glycopyrrolate) New Drug Application for Chronic Obstructive Pulmonary Disease (COPD)
  • Posted Notice of Convocation of the 197th Annual Shareholders' Meeting
  • Sumitomo Dainippon Pharma Announces Voluntary Adoption of International Financial Reporting Standards (IFRS)
  • Sumitomo Dainippon Pharma announces personnel change
  • Sumitomo Dainippon Pharma announces the Clinical Data will be presented at ASCO 2017
  • Posted Video of Financial Results for FY2016 [Webcast]
  • Sumitomo Dainippon Pharma Announces Dividends (Including Special Dividends) of Surplus
  • Sumitomo Dainippon Pharma announces Changes in Board of Directors and Audit & Supervisory Board
  • Presentation Material (Financial Results for FY2016)
  • Supplementary Financial Data for the Year Ended March 31, 2017
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2017 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma announces personnel change
  • Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of Novel Drug Candidate Dasotraline Being Evaluated in the Treatment of Children with Attention Deficit Hyperactivity Disorder (ADHD)
  • Sumitomo Dainippon Pharma Announces Partnership with Bukwang on its Atypical Antipsychotic Agent Lurasidone for Korea
  • Sumitomo Dainippon Pharma Announces Positive Topline Results from a Phase 3 Study of TRERIEF, a therapeutic agent for Parkinson's disease, in the Treatment of Patients with Parkinsonism in Dementia with Lewy Bodies (DLB)
  • Sunovion Announces Utibron Neohaler (indacaterol/glycopyrrolate) Inhalation Powder Now Available in the United States
  • Toray Receives Japanese Approval for an Additional Formulation of Pruritus Treatment REMITCH OD TABLETS 2.5μg
  • Sumitomo Dainippon Pharma announces Changes in Executive Officers
  • Sumitomo Dainippon Pharma Announces New Chief Executive Officer at Boston Biomedical, Inc. and Establishment of Global Head of Oncology
  • Posted Video of R&D Meeting [Webcast]
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
  • Posted Presentation Material (R&D Meeting)
  • Sumitomo Dainippon Pharma announces Allogeneic iPS cell-derived Dopaminergic Neural Progenitor Cells Designated a "SAKIGAKE" Product by Japan's Ministry of Health, Labour and Welfare
  • Sumitomo Dainippon Pharma Announces the Approval of an Atypical Antipsychotic Blonanserin (Brand Name in Japan: LONASEN) in China
  • Sumitomo Dainippon Pharma announces Changes of Representative Directorsand Executive Officers
  • Posted Conference Call for Third Quarter Financial Results for FY2016 [Webcast]
  • Sunovion’s Latuda (lurasidone HCl) Receives FDA Approval to Treat Adolescents with Schizophrenia
  • Presentation Material (Third Quarter Financial Results for FY2016)
  • Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2017
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2017 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma Completes Acquisition of Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
  • Sumitomo Dainippon Pharma Announces Clinical Data of Investigational Cancer Stemness Inhibitor Napabucasin were presented at 2017 ASCO GI Symposium
  • Sumitomo Dainippon Pharma to Participate in Global Partnership "Access Accelerated" to Address Non-Communicable Diseases
  • Sunovion Announces Pivotal Study Results for Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms in Children Compared to Placebo
  • Sunovion Announces Top-line Results from Studies Evaluating Dasotraline in Adults with Binge Eating Disorder and Attention Deficit Hyperactivity Disorder
  • Posted Conference Call for Acquisition of Tolero Pharmaceuticals, Inc. [Webcast]
  • Sumitomo Dainippon Pharma to Conduct Meropenem Business in Five Countries of South-East Asia and Hong Kong
  • Sunovion Enters into License Agreement for Three Approved Treatment Options for People with COPD in the U.S.
  • Teleconference Material (Acquisition of Tolero Pharmaceuticals, Inc.)
  • Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
  • Sumitomo Dainippon Pharma Announces Merger of US consolidated subsidiaries
  • Posted Factbook 2016 ver.2
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
  • Sumitomo Dainippon Pharma announces the data of an investigational WT1 cancer peptide vaccine, DSP-7888 will be presented at the ASH 2016
  • Posted Video of Second Quarter Financial Results for FY2016 [Webcast]
  • Presentation Material (Second Quarter Financial Results for FY2016)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2017
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2017 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma Announces the Establishment of a Subsidiary for Promotion of Authorized Generics and others
  • Sumitomo Dainippon Pharma's U.S. Subsidiary Sunovion Pharmaceuticals Completes Acquisition of Cynapsus Therapeutics Inc. (Canadian Specialty Central Nervous System Biotechnology Company)
  • Sumitomo Dainippon Pharma Announces the Results of Its Early Retirement Program Offer for Japanese Employees
  • Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the Half-Year Ended September 30, 2016
  • Sunovion Announces FDA Filing Acceptance of New Drug Application for SUN-101/eFlow for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
  • Sumitomo Dainippon Pharma announces the final data analysis of a global phase 3 study of an investigational anti-cancer drug Napabucasin (CO.23 study) will be presented at the ESMO 2016 Congress
  • Posted Annual Report 2016
  • Sunovion Announces Results from Pivotal Study Evaluating Novel Drug Candidate Dasotraline in Children with ADHD
  • Sumitomo Dainippon Pharma's U.S. Subsidiary Sunovion to Acquire Cynapsus Therapeutics Inc. (Canadian Specialty Central Nervous System Biotechnology Company)
  • Sumitomo Dainippon Pharma announces offering an Early Retirement Program to Japanese Employees and Reduction in Executive Remuneration
  • Posted Conference Call for First Quarter Financial Results for FY2016 [Webcast]
  • Sunovion Submits New Drug Application for SUN-101/eFlow to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
  • Presentation Material (First Quarter Financial Results for FY2016)
  • Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2017
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2017 [Japanese GAAP] (Unaudited)
  • Sysmex, Healios and Sumitomo Dainippon Pharma Begin Joint R&D Related to Pre-Transplant Immune Reaction Testing Method for Retinal Pigment Epithelial Cells (RPE Cells) Derived from Allogeneic iPS Cells
  • Sumitomo Dainippon Pharma Listed in FTSE4Good Index Series of Socially Responsible Investment for the 14th Consecutive Year
  • Posted FactBook 2016
  • Posted the posters regarding napabucasin（BBI608） and amcasertib（BBI503） were presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting on the website of Boston Biomedical
  • Posted Notice of Convocation of the 196th Annual Shareholders’ Meeting
  • Sumitomo Dainippon Pharma announces Clinical Data of Investigational anti-cancer drugs Napabucasin and Amcasertib in Multiple Cancer Types at ASCO 2016
  • Posted Video of Financial Results for FY2015 [Webcast]
  • Presentation Material (Financial Results for FY2015)
  • Supplementary Financial Data for the Year Ended March 31, 2016
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2016 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma announces Change of Directors
  • Sunovion Pharmaceuticals Inc. Announces Positive Results from Two Phase 3 Clinical Studies Evaluating SUN-101/eFlow (glycopyrrolate) in People with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease (COPD)
  • Sumitomo Dainippon Pharma Contributes to Kumamoto Earthquake Relief Efforts in Japan
  • Kyoto University and Sumitomo Dainippon Pharma Launch Second Stage of Joint Research Project for Innovative Oncology Therapeutics (DSK Project)
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
  • Posted Conference Call for Third Quarter Financial Results for FY2015 [Webcast]
  • Presentation Material (Third Quarter Financial Results for FY2015)
  • Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2016
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2016 [Japanese GAAP] (Unaudited)
  • Boston Biomedical’s Investigational Cancer Stem Cell Pathway Inhibitor, Napabucasin (BBI608), Featured at the ASCO 2016 Gastrointestinal Cancers Symposium
  • Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
  • Replaced slides of the R&D meeting presentation material as of December 9th (Revised: deleted the images of CT-scan on the slide 63 and 64)
  • Posted Video of R&D Meeting [Webcast]
  • Posted Presentation Material (R&D Meeting)
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
  • Posted Factbook 2015 ver.2
  • Received the Award for the First Time with the Pen-Style Medical Injector. A Unique Injector, "Ateos" for "Trulicity" Type 2 Diabetes Treatment Received "Good Design Gold Award."
  • Posted Video of Second Quarter Financial Results for FY2015 [Webcast]
  • Presentation Material (Second Quarter Financial Results for FY2015)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2016
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2016 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the Half-Year Ended September 30, 2015
  • Sumitomo Dainippon Pharma Celebrates 10th Anniversary of the Merger
  • Posted Basic Policy on Corporate Governance
  • "Ateos" Injector for "Trulicity" Type 2 Diabetes Treatment Wins "Good Design Award 2015" and Selected as One of Good "Design Best 100 2015"
  • Market Release of "Trulicity Subcutaneous Injection 0.75mg Ateos"Once-Weekly Type 2 Diabetes Treatment ： GLP-1 Receptor Agonist
  • Posted Annual Report 2015
  • Sumitomo Dainippon Pharma announces personnel change
  • Sunovion Announces FDA Approval of a New Indication for Aptiom (eslicarbazepine acetate) as Monotherapy for Partial-Onset Seizures
  • Posted Conference Call for First Quarter Financial Results for FY2015 [Webcast]
  • Presentation Material (First Quarter Financial Results for FY2015)
  • Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2016
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2016 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma,CiRA and Hitachi Start Joint Research on Development of Key Evaluation Technologies: Evaluation for Industrialization in the Field of Regenerative Medicine -Toward Application of Human iPS Cell for Parkinson's Disease Treatment-
  • Sumitomo Dainippon Pharma Announces Commercialization Partnership with Servier on Its Atypical Antipsychotic Agent Latuda (lurasidone hydrochloride) for Australia
  • Eli Lilly Japan and Sumitomo Dainippon Pharma signed a sales collaboration agreement for a once-weekly GLP-1 receptor agonist "Trulicity Subcutaneous Injection 0.75 mg Ateos"
  • Sumitomo Dainippon Pharma announces Changes in Executive Officers and Other Key Positions
  • Posted Factbook 2015
  • JCR and Sumitomo Dainippon Pharma Conclude a Feasibility Study Agreement on Application of the Blood-Brain Barrier Penetration Technology in Psychiatry and Neurology Area
  • Boston Biomedical Data at ASCO 2015 Highlights Potential of Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types
  • Posted Notice of Convocation of the 195th Annual Shareholders’ Meeting
  • Toray Receives Japanese Approval for Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 μg and Promotion to Start
  • Sunovion Pharmaceuticals Inc. Announces Positive Results for Latuda (lurasidone HCl) in First Placebo-Controlled Trial of Patients with Major Depressive Disorder with Mixed (Subsyndromal Hypomanic) Features
  • Posted Video for Financial Results for FY2014 [Webcast]
  • Boston Biomedical to Highlight Data Examining Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types at ASCO 2015
  • "Corporate profile" An English version and a Japanese version are updated.
  • Presentation Material (Financial Results for FY2014)
  • Supplementary Financial Data for the Year Ended March 31, 2015
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2015 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate their Agreement for the Joint Development and Exclusive Commercialization of Latuda (lurasidone) - an Atypical Antipsychotic Agent, in Europe
  • Sumitomo Dainippon Pharma Makes a Follow-up Announcement on the Preliminary Findings from a Phase III Clinical Study (PASTEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
  • Sumitomo Dainippon Pharma Revises Its Basic Policy on Internal Control System
  • Sumitomo Dainippon Pharma announces personnel changes
  • Toray Applies for Japanese Approval of Additional Indication of Pruritus Treatment REMITCH CAPSULES 2.5 μg and Notice Regarding Promotion Tie-up
  • Sumitomo Dainippon Pharma announces Organizational Realignment and Changes Related to Officers and Other Key Positions
  • Sunovion Pharmaceuticals Inc. Announces Initiation of Phase 3 Clinical Trial Program for SUN-101/eFlow® (Glycopyrrolate) in Moderate-to-Very SevereChronic Obstructive Pulmonary Disease (COPD)
  • Posted Conference Call for Third Quarter Financial Results for FY2014 [Webcast]
  • Presentation Material (Third Quarter Financial Results for FY2014)
  • Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2015
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2015 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma Announces Collaboration on Lurasidone, an Atypical Antipsychotic Agent, for Thailand, Singapore and Hong Kong
  • Sunovion Pharmaceuticals Inc. Files Patent Infringement Lawsuits Regarding Latuda
  • Sunovion Pharmaceuticals Inc. Announces FDA Acceptance for Review of Supplemental New Drug Application for the Use of Aptiom (eslicarbazepine acetate) as Monotherapy Treatment for Partial Onset Seizures
  • Sumitomo Dainippon Pharma Announces Reorganization of Production Sites
  • Sumitomo Dainippon Pharma Announces Preliminary Findings from a Phase III Clinical Study (PASTEL Study) of Lurasidone, an Atypical Antipsychotic Agent, in the Treatment of Patients with Schizophrenia
  • Investigational Drug Dasotraline Significantly Improved Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in a Placebo-Controlled Study in Adults
  • Posted Factbook 2014 ver.2
  • Sumitomo Dainippon Pharma obtains Approval in Japan for Partial Change of the Approved Indication to "Type 2 Diabetes" for SUREPOST, a Rapid-acting Insulin Secretagogue
  • Posted Video for Second Quarter Financial Results for FY2014 [Webcast]
  • Sumitomo Dainippon Pharma Announces Organizational Realignment, and Changes in Executive Officers and Other Key Positions
  • Presentation Material (Second Quarter Financial Results for FY2014)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2015
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2015 [Japanese GAAP] (Unaudited)
  • Sumitomo Dainippon Pharma Announces Transfer of a Fixed Asset
  • Announcement of termination of co-promotion of anti-depressant, Paxil CR Tablets
  • Posted Annual Report 2014
  • Sunovion Pharmaceuticals Inc. to Divest Xopenex (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc.
  • Sumitomo Dainippon Pharma Acquires Patent License from DNAVEC On Clinical-grade iPS Cell Production Technology
  • Sumitomo Dainippon Pharma and SanBio Conclude Joint Development and License Agreement for North America With Respect to SB623, a Therapy for Stroke
  • Sumitomo Dainippon Pharma Announces Transfer of Certain Fixed Assets
  • Latuda (lurasidone), a New Atypical Antipsychotic Agent for Adults with Schizophrenia, Now Available in the UK, Offers a Combination of Efficacy with Tolerability
  • Posted Conference Call for First Quarter Financial Results for FY2014 [Webcast]
  • Presentation Material (First Quarter Financial Results for FY2014)
  • Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2015
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2015 (Unaudited)
  • Sumitomo Dainippon Pharma Announces Revisions to Its Financial Forecasts for the Half-Year Ending September 30, 2014
  • Sumitomo Dainippon Pharma announces Investment in a New Venture Capital Fund
  • Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
  • Transfer of Marketing Rights for "Inteban", "Catlep" and "Drenison"
  • Posted Factbook 2014
  • Sumitomo Dainippon Pharma announces Change of the Company’s English trade name
  • Dainippon Sumitomo Pharma announces the effects of closure to further patient accrual on its CO.23 study: a phase III global colorectal carcinoma monotherapy trial
  • Dainippon Sumitomo Pharma announces clinical data of anti-cancer drugs BBI608 and BBI503 were presented at the 2014 ASCO Annual Meeting
  • Posted Notice of Convocation of the 194th Annual Shareholders’ Meeting
  • Dainippon Sumitomo Pharma and Daiichi Sankyo Cooperate on Lurasidone, an Atypical Antipsychotic Agent, in Four South American Countries
  • Posted Conference Call for closure to further patient accrual on CO.23 study: a phase III global colorectal carcinoma monotherapy trial [Webcast]
  • Dainippon Sumitomo Pharma announces closure to furtherpatient accrual on its CO.23 study: a phase III global colorectal carcinoma monotherapy trial
  • Joint Investment into Create Vaccine Company, Ltd.
  • Dainippon Sumitomo Pharma Announces Change of the Company’s English trade name and Partial Amendments to Its Articles of Incorporation
  • Dainippon Sumitomo Pharma announces clinical data of anti-cancer drugs BBI608 and BBI503 will be presented at the 2014 ASCO Annual Meeting
  • Posted Video for Financial Results for FY2013 [Webcast]
  • Presentation Material (Financial Results for FY2013)
  • Supplementary Financial Data for the Year Ended March 31, 2014
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2014 [Japanese GAAP] (Unaudited)
  • Dainippon Sumitomo Pharma announces Change of Directors
  • Dainippon Sumitomo Pharma announces Organizational Realignment and Changes in Executive Officers
  • Dainippon Sumitomo Pharma announces personnel changes
  • Once-Daily Aptiom (eslicarbazepine acetate) for the Adjunctive Treatment of Partial-Onset Seizures Now Available in U.S. Pharmacies
  • Dainippon Sumitomo Pharma Announces Revisions to Its Financial Forecasts for the Year Ended March 31, 2014
  • Dainippon Sumitomo Pharma Announces Health Canada Approval of LATUDA (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Patients with Bipolar Depression
  • Dainippon Sumitomo Pharma and Takeda Announce the European Marketing Authorization for Latuda (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
  • Dainippon Sumitomo Pharma announces Changes in Executive Officers and Other Key Positions
  • Dainippon Sumitomo Pharma Announces the Marketing Authorization in Australia for Atypical Antipsychotic Agent Latuda
  • Dainippon Sumitomo Pharma Exhibits Heritages of Doshomachi - "The Pharmacy Street" Along with the Company's Century-Old History
  • Posted Video for R&D meeting [Webcast]
  • Healios and Dainippon Sumitomo Pharma establish a joint venture company for regenerative medicine and cell therapy business
  • Posted Presentation Material for R&D Meeting
  • Dainippon Sumitomo Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
  • Transfer of Marketing Rights for "Inteban", "Catlep" and "Drenison"
  • Chelsea Therapeutics Obtains US FDA Accelerated Approval on "NORTHERA"
  • Posted Conference Call for Third Quarter Financial Results for FY2013 [Webcast]
  • Dainippon Sumitomo Pharma Deepens Cooperation with Edison Pharmaceuticals for Therapeutic Agents for Mitochondria Disease --- Amends the License Agreement and Concludes a Joint Research Agreement and a Stock Purchase Agreement ---
  • Presentation Material (Third Quarter Financial Results for FY2013)
  • Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2014
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2014 (Unaudited)
  • Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia
  • Global Collaboration Forms to Advance Japanese TB Vaccine Technology
  • Dainippon Sumitomo Pharma submits an application for partial change of the approved indication to "Type 2 Diabetes" for SUREPOST, a rapid-acting insulin secretagogue
  • Dainippon Sumitomo Pharma Sets Up the Oncology Clinical Development Unit
  • Dainippon Sumitomo Pharma obtains approval in Japan of a partial change in the approved dosage and administration of MEROPEN, a carbapenem antibiotic preparation, when used for the treatment of bacterial meningitis
  • Sunovion Pharmaceuticals Inc. Presents Positive Results From Two Phase 3 Studies of Once-Daily Aptiom(eslicarbazepine acetate) as Monotherapy Treatment for Partial-Onset Seizures
  • Sunovion Pharmaceuticals Inc. Presents Phase 3 Pooled Analysis of Once-Daily Aptiom (eslicarbazepine acetate) as Adjunctive Treatment for Partial-Onset Seizures
  • Posted Factbook 2013 ver.2
  • Healios and Dainippon Sumitomo Pharma form an alliancein regenerative medicine and cell therapy--- Joint development of the world’s first regenerative medicine/cell therapy business based on iPS cell technology ---
  • Presentation material of press conference (Healios and DSP: Alliance for Japanese market-iPS cell technology into practical use-)
  • Sunovion Pharmaceuticals Inc. Announces FDA Approval of Aptiom (eslicarbazepine acetate) as Once-Daily Adjunctive Treatment of Partial-Onset Seizures
  • A Basic Agreement Reached for Joint Development of New TB Vaccines
  • Sunovion Announces Publication of Two Pivotal Studies Supporting FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression in The American Journal of Psychiatry
  • Financial Results for FY2013 Apr.-Sep. (Apr. 1 to Sep. 30, 2013)
  • Dainippon Sumitomo Pharma Announces Posting of Extraordinary Loss (Impairment Loss)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2014
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2014 [Japanese GAAP] (Unaudited)
  • Dainippon Sumitomo Pharma Announces Variances between Its Financial Forecasts and the Actual Results for the Half-Year Ended September 30, 2013 and Revisions to Its Financial Forecasts for the Full Fiscal Year
  • Application for Marketing Approval Submitted in Taiwan for Atypical Antipsychotic Agent Lurasidone
  • Posted Annual Report 2013
  • Dainippon Sumitomo Pharma to Establish an Anti-Cancer Drugs Sales Company in the U.S.
  • Dainippon Sumitomo Pharma submits an application for an atypical antipsychotic blonanserin (Brand name in Japan: LONASEN) in China
  • Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance for Review of the New Drug Submission of eslicarbazepine acetate as a Once-Daily Adjunctive Therapy for PartialonsetSeizures in Adults with Epilepsy
  • Sunovion Reports Eslicarbazepine Acetate Meets Primary Endpoint in Two Phase 3 Monotherapy Studies for Partial-onset Seizures in Adults with Epilepsy
  • DSP and Takeda Announce Approval of the Marketing Authorization Application for Atypical Antipsychotic Agent Lurasidone in Switzerland
  • Dainippon Sumitomo Pharma To Set Up the Regenerative & Cellular Medicine Office
  • Application Submission for Approval for the Stability-Improved Formulation of Limaprost, an Oral Prostaglandin E1 Analogue in Japan
  • Presentation Material (First Quarter Financial Results for FY2013)
  • Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2014
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2014 (Unaudited)
  • Dainippon Sumitomo Pharma to Have Two Head Offices
  • Sunovion Pharmaceuticals Inc. Announces FDA Approval of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Bipolar Depression
  • Posted Factbook 2013
  • Dainippon Sumitomo Pharma announces the launch of anti-hypertension drug "AVAPRO Tablets 200mg"
  • Dainippon Sumitomo Pharma announces BBI608 Phase 1/2 Clinical Study Data (Dose-Escalation Study) was presented at the 2013 ASCO Annual Meeting
  • Dainippon Sumitomo Pharma Completes Construction on New Chemistry Research Building
  • Dainippon Sumitomo Pharma announces BBI608 Clinical Study Data to be presented at the 2013 ASCO Annual Meeting
  • Dainippon Sumitomo Pharma announces BBI608 Phase 1 Clinical Study Data to be presented at the 2013 ASCO Annual Meeting
  • Presentation Material (Financial Results for FY2012)
  • Supplementary Financial Data for the Year Ended March 31, 2013
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2013 [Japanese GAAP] (Unaudited)
  • Change of Directors and Audit & Supervisory Board Members
  • Ono and Dainippon Sumitomo reach agreement on expanding business relating to Limaprost into China
  • Dainippon Sumitomo Pharma Submits Marketing Authorization Application in Australia for Atypical Antipsychotic Agent Lurasidone
  • Dainippon Sumitomo Pharma and Chugai Pharmaceutical Terminate Joint Development of Cancer Vaccine
  • Dainippon Sumitomo Pharma announces name change of its European subsidiary to Sunovion Pharmaceuticals Europe
  • Dainippon Sumitomo Pharma signs a License Agreement with Edison Pharmaceuticals for therapeutic agents for mitochondria disease
  • Retina Institute Japan and Dainippon Sumitomo Pharma form a capital alliance towards the development of Nobel Prize winning iPS cell technology
  • Dainippon Sumitomo Pharma and Nippon Shinyaku conclude a license agreement for SMP-986, a therapeutic agent for urology
  • Dainippon Sumitomo Pharma announces reorganization of its Research and Development
  • Sunovion Announces FDA Acceptance for Review of New Drug Application Resubmission for STEDESA (eslicarbazepine acetate) as a Once-Daily Adjunctive Therapy for Partial-onset Seizures in Adults with Epilepsy
  • Dainippon Sumitomo Pharma obtains approval for SUREPOST, a rapid-acting insulin secretagogue, for the additional indications of combination therapy with biguanides and with thiazolidinediones
  • Third Mid-term Business Plan Presentation (February 19, 2013) Webcast available
  • Dainippon Sumitomo Pharma announces its Third Mid-term Business Plan
  • Presentation Material (Third Mid-term Business Plan)
  • Presentation Material (Third Quarter Financial Results for FY2012)
  • Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2013
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2013 (Unaudited)
  • Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue
  • Dainippon Sumitomo Pharma files an application in Japan for a partial change in the approved dosage and administration of MEROPEN, a carbapenem antibiotic preparation, when used for the treatment of bacterial meningitis
  • Dainippon Sumitomo Pharma establishes a Subsidiary in Singapore
  • Signing a license agreement and a joint research agreement for new anti-cancer drug candidate compounds targeting the Ras signaling pathway
  • Posted Factbook 2012 ver.2
  • Dainippon Sumitomo Pharma and Shionogi Announce the NHI Drug Price Standard Listing and Launch of anti-hypertension drug "AIMIX Combination Tablets LD/HD"
  • Presentation Material (Second Quarter Financial Results for FY2012)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2013
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2013 (Unaudited)
  • Sunovion Pharmaceuticals Inc. Announces FDA Acceptance of Two Supplemental New Drug Applications for the Use of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
  • DSP and Takeda Announce the Acceptance of the European Medicines Agency Submission of an Atypical Antipsychotic Agent Lurasidone
  • Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for "AIMIX Combination Tablets LD/HD"
  • Sunovion Pharmaceuticals Canada Inc. Announces the Launch of Once-Daily Latuda (lurasidone HCl) for the Treatment of Patients with Schizophrenia
  • Sunovion Pharmaceuticals Files Two Supplemental New Drug Applications Seeking Approval for the use of Latuda (lurasidone HCl) as Monotherapy and Adjunctive Therapy in Adult Patients with Depressive Episodes Associated with Bipolar I Disorder
  • Sunovion Pharmaceuticals Inc. Completes Acquisition of Elevation Pharmaceuticals, Inc.
  • Dainippon Sumitomo Pharma submits an application for anticancer antibiotic amrubicin HCI (Brand name in Japan: CALSED) in China
  • Dainippon Sumitomo Pharma Co., Ltd.'s U.S. Subsidiary Sunovion Pharmaceuticals Inc. to Acquire Elevation Pharmaceuticals, Inc. (US Biopharmaceutical Company)
  • Dainippon Sumitomo Pharma announces organizational changes:Establishment of the "DSP Cancer Institute"
  • Sunovion Pharmaceuticals Inc. Announces Nationwide Availability of ZETONNA (ciclesonide) Nasal Aerosol for Allergic Rhinitis
  • Presentation Material (First Quarter Financial Results for FY2012)
  • Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2013
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2013 (Unaudited)
  • Revision of Financial Forecasts
  • Dainippon Sumitomo Pharma and Nitto Denko Joint Development Phase 2 studies start on the world's first transdermal patch formulation for schizophrenia treatment
  • SUNOVION PHARMACEUTICALS RECEIVES SIX MONTH U.S. PEDIATRIC EXCLUSIVITY FOR LUNESTA (eszopiclone)
  • Dainippon Sumitomo Pharma announces the launch of Sleep Inducing Treatment "Zolpidem tartrate tablets 5mg/10mg [DSP]"
  • Posted Factbook 2012
  • Anti-depressant Paxil CR Tablets newly launched
  • Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for long-acting calcium antagonist AMLODIN tablets/OD tablets for the Additional Indication of "Hypertension in pediatric patients"
  • Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of Once-Daily LATUDA (lurasidone HCl) for the Treatment of Patients with Schizophrenia
  • Dainippon Sumitomo Pharma and Shionogi to Sign a License Agreement for the Co-marketing of “DSP-8153”, Combination Product of Anti-hypertension Drugs irbesartan and amlodipine besilate
  • Notice of Convocation of the 192nd Annual Shareholders' Meeting
  • Sunovion Pharmaceuticals settles dispute on BROVANA patent litigation
  • Presentation Material (Financial Results for FY2011)
  • Supplementary Financial Data for the Year Ended March 31, 2012
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2012 (Unaudited)
  • Change of Members of Board of Directors and Executive Officer
  • New Study Shows Patients Can Effectively be Switched to Latuda (lurasidone HCl) from Other Antipsychotic Agents
  • SUNOVION ANNOUNCES UPCOMING AVAILABILITY OF ZETONNA (ciclesonide) NASAL AEROSOL, A NON-AQUEOUS, DRY NASAL AEROSOL SPRAY FOR ALLERGIC RHINITIS
  • Latuda (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of Patients with Schizophrenia
  • Dainippon Sumitomo Pharma Co. Reports that Latuda (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression (Updated version)
  • Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Boston Biomedical, Inc. (US Biotechnology Company)
  • Change of Executive Officer
  • Dainippon Sumitomo Pharma Co. Reports that Latuda (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase III Trials in Bipolar I Depression
  • Dainippon Sumitomo Pharma submits an application for SUREPOST, a rapid-acting insulin secretagogue, for the additional indication of combination therapy with thiazolidinediones and with biguanides
  • Change of Executive Officer
  • GlaxoSmithKline and Dainippon Sumitomo Pharma commence the co-promotion of anti-depressant Paxil CR Tablets
  • Presentation Material (Acquisition of Boston Biomedical Inc.)
  • Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical Inc. (US Biotechnology Company)
  • Change of Representative Directors and Executive Officers
  • Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for Sleep Inducing Treatment "Zolpidem tartrate tablets 5mg/10mg [DSP]"
  • Dainippon Sumitomo Pharma Submits Application Based on Public Knowledge for long-acting calcium antagonist AMLODIN tablets/OD tablets for the Additional Indication of "Hypertension in pediatric patients"
  • Presentation Material (Third Quarter Financial Results for FY2011)
  • Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2012
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2012 (Unaudited)
  • Revision of Financial Forecasts for the Year Ending March 31, 2012
  • Dainippon Sumitomo Pharma Begins Construction on New Chemistry Research Building
  • Announcement of basic agreement concerning co-promotion of anti-depressant Paxil® CR Tablets
  • Posted Factbook 2011 ver.2
  • STEDESA™ clinical data presented at 2011 American Epilepsy Society Annual Meeting
  • Dainippon Sumitomo Pharma and Yoshitomiyakuhin terminate co-promotion of antipsychotics, LONASEN and LULLAN
  • Dainippon Sumitomo Pharma announces application for manufacturing and marketing approval for "DSP-8153", combination product of irbesartan and amlodipine besilate
  • Dainippon Sumitomo Pharma announces the launch of Alzheimer's Disease Treatment Donepezil hydrochloride tablets/OD tablets 3mg/5mg "DSP"
  • Presentation Material (Second Quarter Financial Results for FY2011) (With additional reference slides)
  • Redesigned CSR Activities
  • Presentation Material (Second Quarter Financial Results for FY2011)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2012
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2012 (Unaudited)
  • Difference from Financial Forecasts for the Second Quarter of the Year Ending March 31, 2012 and Revision of Financial Forecasts for the Year Ending March 31, 2012
  • LATUDA (lurasidone HCl) Shown to be Non-Inferior to SEROQUEL XR (quetiapine fumarate XR) in Risk for Relapse in a 12-Month, Double-Blind Extension Study of Adult Patients with Schizophrenia
  • Posted Annual Report 2011
  • Dainippon Sumitomo Pharma Co., Ltd. Announces Issuance of Unsecured Straight Bonds
  • Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Acceptance of Lurasidone New Drug Submission for Treatment of Schizophrenia
  • Posted Presentation Material (First Quarter Financial Results for FY2011)
  • Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2012
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2012 (Unaudited)
  • "Corporate profile" An English version and a Japanese version are updated.
  • Dainippon Sumitomo Pharma obtains manufacturing and marketing approval for Alzheimer's Disease Treatment "Donepezil hydrochloride tablets/OD tablets 3mg/5mg [DSP]".
  • Sunovion Announces FDA Acceptance of New Drug Application for Ciclesonide HFA Nasal Aerosol
  • Collaborative Research on Apoptosis Inhibitor of Macrophages (AIM)
  • Announcement on Co-development and Co-marketing Agreement for Carpal-tunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue
  • Results of a Phase II Clinical Trial for Ranirestat - Therapeutic Agent for Diabetic Complications
  • Dainippon Sumitomo Pharma announces Pan-Asia study results for lurasidone, an atypical antipsychotic agent, in the treatment of schizophrenia
  • Change of Members of Board of Directors, Corporate Auditors and Executive Officers
  • Change of Representative Directors
  • Presentation Material (Financial Results for FY2010)
  • Supplementary Financial Data for the Year Ended March 31, 2011
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2011 (Unaudited)
  • Dainippon Sumitomo Pharma announces the launch of SUREPOST, a rapid-acting insulin secretagogue
  • Dainippon Sumitomo Pharma and Maruho Enter into a License Agreement for a Novel Topical Analgesic Drug
  • CiRA and DSP Research the Creation of a New Treatment for Rare Intractable Diseases
  • Dainippon Sumitomo Pharma Co., Ltd. and Boston Biomedical, Inc. Enter Strategic Partnership on Anti-Cancer Drugs Targeting Cancer Stem Cells
  • Impact of the Great East Japan Earthquake (Part 2)
  • Dainippon Sumitomo Pharma Group Contributes to Earthquake Relief Efforts in Japan (Part 2)
  • DSP and Takeda Sign Development and Commercialization Agreement for an Atypical Antipsychotic Agent Lurasidone in Europe
  • Takeda and DSP Sign Development, Manufacturing and Commercialization Agreement for a Cephem Antibiotic Ceftaroline in Japan
  • Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
  • Revision of Financial Forecasts for the Year Ending March 31, 2011
  • Impact of the Tohoku Earthquake
  • Dainippon Sumitomo Pharma Group Contributes to Earthquake Relief Efforts in Japan
  • Laboratory for Malignancy Control Research
    New cancer research facility in Kyoto University supported by Dainippon Sumitomo Pharma
  • Dainippon Sumitomo Pharma Contributes to Earthquake Relief Efforts in Japan
  • Approval obtained for partial change in dosage and administration of MEROPEN, a carbapenem antibiotic preparation
  • Dainippon Sumitomo Pharma Co., Ltd. Announces Issuance of Unsecured Straight Bonds
  • Execution of the definitive agreement for the assignment of "Radarcirc" business
  • Dainippon Sumitomo Pharma Co. Ltd. (DSP) Announces Launch of Latuda (lurasidone HCl) in the United States
  • Posted Presentation Material (Third Quarter Financial Results for FY2010)
  • Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2011
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2011 (Unaudited)
  • Revision of Financial Forecasts for the Fiscal Year Ending March 31, 2011
  • Completion of Long-Term Phase 3 Safety Trial for Latuda (lurasidone HCl)
  • Posted Presentation Material for LATUDA Meeting
  • SUREPOST, a rapid-acting insulin secretagogue, obtains a manufacturing and marketing approval
  • Joint development of therapeutic cancer vaccine WT4869
  • Merger of the Chinese subsidiaries completed
  • Latuda (lurasidone HCl) Significantly Improves Symptoms of Schizophrenia in Fifth Positive Placebo-Controlled Study
  • "Hidden kidney damage" behind hypertension revealed by a large-scale survey
  • LATUDA (lurasidone HCl) SIGNIFICANTLY REDUCED SYMPTOMS OF SCHIZOPHRENIA IN NEW CLINICAL STUDY
  • Posted Presentation Material for Analysts Meeting (Second Quarter Financial Results for FY2010)
  • Posted Presentation Material for Press Conference (Second Quarter Financial Results for FY2010)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2011
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2011 (Unaudited)
  • Revision of Financial Forecasts for the Fiscal Year Ending March 31, 2011
  • FDA APPROVES ONCE-DAILY LATUDA (lurasidone HCL) FOR THE TREATMENT OF PATIENTS WITH SCHIZOPHRENIA
  • SUNOVION PHARMACEUTICALS INC. ANNOUNCES COMPANY NAME CHANGE
  • Dainippon Sumitomo Pharma Global Website Opened.
  • "Research and Development" are updated.
  • Notice of launching of LONASEN in Korea
  • Dainippon Sumitomo Pharma and SanBio Collaborate on Cell Therapy for Stroke Recovery
  • Posted Annual Report 2010
  • Launch of STEROP, an anti-inflammatory steroid eye-drop
  • Posted Presentation Material (First Quarter Financial Results for FY2010)
  • Supplementary Financial Data for the First Quarter of the Year Ending March 31, 2011
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2011 (Unaudited)
  • Revision of Financial Forecasts for the Fiscal Year Ending March 31, 2011
  • SEPRACOR INC. TO BECOME SUNOVION PHARMACEUTICALS INC.
  • SEPRACOR REPORTS PRELIMINARY RESULTS FROM A SECOND PHASE III STUDY FOR OMNARIS HFA NASAL AEROSOL IN SEASONAL ALLERGIC RHINITIS
  • "DS Pharma Animal Health Co., Ltd." formed
  • "DSP Gokyo Food & Chemical Co., Ltd." inaugurated
  • Notice of Convocation of the 190th Annual Shareholders' Meeting
  • Application for partial change of approval of the dosage and administration of MEROPEN, a carbapenem antibiotic preparation
  • JCR Pharmaceuticals and Dainippon Sumitomo Pharma sign an Assignment Agreement for the growth hormone business
  • Posted Presentation Material (Financial Results for FY2009)
  • Supplementary Financial Data for the Year Ended March 31, 2010
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2010 (Unaudited)
  • FDA PROVIDES COMPLETE RESPONSE TO SEPRACOR’S NEW DRUG APPLICATION FOR STEDESA
  • Announcement of a decision of Supreme Court of Japan about the suit
  • Notice of launching of LONASEN tablets 8mg
  • Launch of oral hypoglycemic drug METGLUCO
  • Dainippon Sumitomo Pharma America Announces FDA Acceptance of Lurasidone New Drug Application for Treatment of Schizophrenia
  • Change of Executive Officers and Merger of Two Subsidiaries in North America
  • Posted Presentation Material for Analysts Meeting of Second Mid-term Business Plan (Feb.16, 2010)
  • Second Mid-term Business Plan
  • Posted Presentation Material (Third Quarter Financial Results for FY2009)
  • Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2010
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2010 (Unaudited)
  • Revision of Financial Forecasts for the Year Ending March 31, 2010
  • FDA extends PDUFA action date for STEDESA new drug application
  • DSP Group Contributes to Haiti Earthquake Relief Efforts
  • JCR Pharmaceuticals and Dainippon Sumitomo Pharma sign a Letter of Intent for the assignment and acceptance of the growth hormone business
  • Company Split (Incorporation-type Company Split）of the Company's Animal Health Products business
  • Company Split (Absorption-type Company Split） of the Company's Food & Speciality Products business
  • Oral hypoglycemic drug METGLUCO obtained a manufacturing and marketing approval
  • Acquisition of an additional indication of MEROPEN, a carbapenem antibiotic preparation
  • Dainippon Sumitomo Pharma America Announces the NDA Submission of Lurasidone to the FDA for the Treatment of Schizophrenia
  • SEPRACOR GRANTED PATENT TERM EXTENSION FOR LUNESTA AND PROVIDES UPDATE ON LUNESTA PEDIATRIC STUDIES
  • Notice of launching of therapeutic agent for hepatocellular carcinoma "MIRIPLA"
  • Notice of Restructuring (Company Split) of the Company's Non-pharmaceutical Operations
  • Sepracor　Factbook 2009
  • Posted Presentation Material (Sepracor　Inc. Company Overview -November 12, 2009)
  • Posted Presentation Material (Second Quarter Financial Results for FY2009)
  • Supplementary Financial Data for the Second Quarter of the Year Ending March 31, 2010
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2010 (Unaudited)
  • Difference from Financial Forecasts for the Second Quarter of the Year Ending March 31, 2010 and Revision of Financial Forecasts for the Year Ending March 31, 2010
  • Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Sepracor Inc.
  • Therapeutic agent for hepatocellular carcinoma "MIRIPLA" obtained manufacturing and marketing approval
  • Dainippon Sumitomo Pharma Co., Ltd. Completes Tender Offer for Sepracor Inc.
  • New OD tablet of AMLODIN by original formulation technology "SUITAB-NEX"
  • Dainippon Sumitomo Pharma Co., Ltd. to Acquire U.S.-based Sepracor Inc.
  • LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY
  • Posted Annual Report 2009
  • Posted Presentation Material (First Quarter Financial Results for FY2010)
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2010
  • Announcement of establishment of a holding company in the U.S.
  • Acquisition of an additional indication of AmBisome, a therapeutic agent for systemic fungal infection
  • Lurasidone Meeting
  • Corporate profile update (June 5, 2009)
  • STUDY DEMONSTRATING LURASIDONE IS EFFECTIVE IN PATIENTS WITH SCHIZOPHRENIA PUBLISHED IN THE JOURNAL OF CLINICAL PSYCHIATRY
  • DAINIPPON SUMITOMO PHARMA ANNOUNCES LURASIDONE PHASE III DATA IN PATIENTS WITH SCHIZOPHRENIA
  • Posted Presentation Material (Financial Results for FY2008)
  • Supplementary Financial Data For the Year Ended March 31, 2009
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2009 (Unaudited)
  • Acquisition of an additional indication relating to pretreatment for barium enema X-ray examination by concomitant use of NIFLEC and GASMOTIN
  • Discontinuation of development of AC-3933, a therapeutic agent for dementia
  • Wakunaga appealed to the Supreme Court against the Osaka High Court's decision
  • Announcement of a judgment of the suit (an appeal court decision)
  • Launch of "PRONAMID",a gastro-prokinetic agent for dogs
  • Notice of launching of a new Parkinson's disease drug "TRERIEF"
  • Posted Presentation Material (Third Quarter Financial Results for FY2008)
  • Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2009
  • Parkinson's disease drug "TRERIEF" obtained manufacturing and marketing approval
  • DSP takes over Kyowa Hakko Kirin's manufacturing subsidiary in China.
  • Posted Presentation Material (Second Quarter Financial Results for FY2008)
  • Summary of Consolidated Financial Results for the Second Quarter of the Year Ending March 31, 2009
  • Notice of establishment of Drug Discovery Consortium in neuropsychiatric area
  • Posted Annual Report 2008
  • Posted Presentation Material (First Quarter Financial Results for FY2008)
  • Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2009
  • Notice of launching of Anti-hypertension drug "AVAPRO"
  • Posted Presentation Material (Financial Results for FY2007)
  • Supplementary Financial Data for the Year Ended March 31, 2008
  • Summary of Consolidated Financial Results for the Year Ended March 31, 2008
  • Novel Therapeutic Agent for Allergic Disorders Discovered in Collaboration with AstraZeneca Progresses to Clinical Development Stage
  • Notice of launching of a new antipsychotic LONASEN
  • Anti-hypertension drug "Avapro" obtained manufacturing and marketing approval
  • Discontinuation of Development for an Additional Indication of Cervical Spondylosis of Limaprost Alfadex, an Oral Prostaglandin E1 Derivative Preparation
  • Change of Representative Directors
  • Overview of Consolidated Financial Results for the First Nine Months of the Year Ending March 31, 2008
  • Posted Presentation Material (First Half Financial Results for FY2007)
  • Supplementary of Interim Consolidated Financial Data For The Year Ending March 31, 2008
  • Summary of Interim Consolidated Financial Results For The Year Ending March 31, 2008
  • Dainippon Sumitomo Pharma signs license agreement for a sedative hypnotic agent
  • Overview of Consolidated Financial Results for the First Three Months of the Year Ending March 31, 2008
  • Posted Presentation Material (Financial Results for FY2006)
  • Supplementary Data of Financial Results for The Year Ended March 31, 2007
  • Summary of Consolidated Financial Results for The Year Ended March 31, 2007
  • Posted Presentation Material (R&D Meeting)
  • Investment in bio-venture fund
  • Posted Presentation Material (FY'07-'09 Mid-term Business Plan)
  • Mid-term Business Plan
  • Notice of Conclusion of Absorption-type Demerger Contact Relating to Diagnostics Business Merger
  • Launch of "Replagal3.5mg" for Anderson-Fabry Disease
  • Overview of Consolidated Financial Results for the First Nine Months of the Year Ending March 31, 2007
  • Review of overseas development of Lurasidone (SM-13496), an atypical antipsychotic
  • Revising domestic development plan of AC-5216, an antianxiety/antidepressant agent
  • Notice of Diagnostics Business Merger
  • Posted Presentation Material (First Half Financial Results for FY2006)
  • Supplementary of Interim Consolidated Financial Data For The Year Ending March 31, 2007
  • Summary of Interim Consolidated Financial Results For The Year Ending March 31, 2007
  • Revised March 2007 Interim and Fiscal-Year Financial Estimates
  • Dainippon Sumitomo Pharma and Sumitomo Chemical agree with Pfizer on Settlement of Amlodin Lawsuit
  • Conclusion of an Agreement over Co-promotion of Dops for the Treatment of Orthostatic Hypotension
  • Overview of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2007
  • Partnership Agreements Concerning Anti-Hypertension & Hepatocellular Cancer Drugs Reached
  • English Court denies its jurisdiction over the Amlodin lawsuit brought by Pfizer
  • Launch of AmBisome 50mg for Intravenous Drip Infusion, a Therapeutic Agent for Systemic Fungal Infection
  • Dainippon Sumitomo Pharma and Chelsea Therapeutics International Signed Licensing Agreement for Dops for the treatment of orthostatic hypotension
  • Posted Presentation Material (Financial Results for FY2005, R&D Meeting)
  • Results of Re-employment Assistance Program
  • Summary of Consolidated Financial Results For The Year Ended March 31, 2006
  • Notice of Commemorative Dividend
  • Dainippon Sumitomo Pharma and Eisai Signed Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members
  • Integration of US Subsidiaries and Renaming of European subsidiary
  • Pending Expiration of Cooperative Marketing Agreement between Abbott Japan and Dainippon Sumitomo Pharma
  • Implementation of Re-employment Assistance Program
  • Announcement of Revised Results Forecasts
  • Overview of Consolidated Financial Results for the First Nine Months of Fiscal Year 2005 (Unaudited)
  • Pfizer files lawsuit in England regarding licence for Amlodin
  • Dainippon Sumitomo Pharma Website Opened.
  • Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
  • Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Enter into a Basic Agreement to Merge on October 1, 2005